peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Coffee and notepad

Press releases


18 apr 2024, 07:00 | Regulatory
•    Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease 
•    Cash runway extended into 2026
•    Evan Ballantyne joins Hansa Biopharma as Chief Financial Officer
Load more
Coffee and notepad


Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.